miércoles, 31 de enero de 2018

FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS

U.S. Food and Drug Administration Header

FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS

FDA approved lutetium Lu 177 dotatate (LUTATHERA, Advanced Accelerator Applications USA, Inc.) a radiolabeled somatostatin analog, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. More Information.  January 26, 2018

Other Hematology/Oncology (Cancer) Approvals & Safety Notifications

No hay comentarios:

Publicar un comentario